________________________________________________________________________________________________________________________________

(C) Bellevue Asset Management 2013 - Michael Heider

Bank am Bellevue’s New Head of Research

February 2013. Swiss investment firm Bank am Bellevue (BB Biotech; Bellevue Asset Management) has a new Head of Research for its twelve analysts since February 1. Michael Heider comes from the Zürich subsidiary of stock-trading firm Helvea SA which he left in September 2012 after fifteen months. Before that he worked for Berenberg Bank (Schweiz) AG until 2010 where he started in 2004 and became Managing Director of Berenberg Equity Services in 2005 until its shut down 12 months later. Notwithstanding ups and downs at Berenberg Mr. Heider won several distinguished prizes for his performance in what he called his “stockpicker” approach not focused on a single industry. “Somewhere you always have under-valued stocks” he told during a prize award at Zürich in 2010.

Mr. Heider follows Johannes Borner who moved to Santro Invest AG Pfäffikon (CH) at the end of last year
Expectations are high at Bank am Bellvue. According to the company’s press release (22-02-2013), its Research Team's “top 5 recommendations produced an aggregate return of 28.2% in 2012, which represents an outperformance of 13.8% over the SMI.” and “composite performance, based on all recommendations, was better than the total market performance in 28 of 36 quarters, achieving an average return of 14.4% p.a. versus 3.5% for the SMI.”

Michael Heider (born 1971) studied Economics at Universities Köln (DE), Montpellier (FR) and Marburg (DE). He has an MBA diploma (BWL). End of the nineties he joined Institut für Weltwirtschaft at Kiel (DE)to pursue his career in International Economic Policy Research before moving to Switzerland. ed

Copyright Notice
Please note: You may freely distribute the link to this article. Any copying, distributing, or publishing of the entire article or parts of it (picture included) requires prior written consent by B2Bioworld or by third parties retaining copyrights. All rights reserved.

This editorial article is brought to you free of charge. You may see how we work, investigate issues,
and write up results in articles free of advertising and normally at cost . Enjoy reading

Back to section

Related Editorial Articles

Upcoming opportunities in the German M&A market
Mittelstandsbanken winners of trade sales / BayBG sees changes in the market

Lilly Ventures: Is that worth a dollar, or a million dollars?
Ed Torres, Managing Director of Lilly Ventures on the fund’s input to Eli Lilly’s business development

Novartis: Adhering to Values Pays off
The Swiss/American company continues to expand the biotech therapeutics pipeline / Focus on emerging markets